Lay Line Genomics S.p.a.

Consiglio Nazionale Delle Ricerche

Istituto Superiore Di Sanita

Sara Marinelli

Flaminia Pavone

Gabriele Ugolini

Antonio Cattaneo

Antonino Cattaneo

Siro Luvisetto

Valentina Vacca

Carla Fiorentini

Alessia Fabbri

Ugolini Gabriele

Loredana Falzano

Elisabetta Straface

Walter Malorni

A new therapeutic use of botulinum neurotoxin serotype A (Bont/A) is described, in the therapeutic treatment of paralysis caused by spinal cord injury.

Therapeutic use of the botulinum neurotoxin serotype A

According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.

Method for the potentiation of opioid analgesics effects on pain

Use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA, in particular capable of blocking the biological activity of TrkA, for the preparation of a medicament for treating and/or preventing chronic pain.

Analgesic treatment with prolonged effect

Growing community of inventors

Rome, Italy

Sara Marinelli